杭州功楚生物科技

Gongchu Biotech is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics for "undruggable" targets. Founded by Dr. Gong Chu, a specialist in chemoproteomics, the company leverages a proprietary platform to identify and develop covalent ligands that interact with specific protein residues. Their research focus is primarily on oncology and immunology, aiming to develop first-in-class or best-in-class therapeutics. The company has secured significant investment from leading life science investors such as Lilly Asia Ventures and Qiming Venture Partners to advance its early-stage pipeline.